Page last updated: 2024-12-08

metipamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

metipamide: no further info available 11/86 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135086
CHEBI ID135441
MeSH IDM0144176

Synonyms (12)

Synonym
unii-n9q32yur4e
n9q32yur4e ,
metipamide
CHEBI:135441
hypotylin (tn)
D08208
85683-41-6
benzoic acid, 3-(aminosulfonyl)-4-chloro-, 2-methyl-2-phenylhydrazide
2-chloro-5-[(n-methylanilino)carbamoyl]benzenesulfonamide
AKOS024344623
DTXSID00234964
2-chloro-5-((2-methyl-2-phenylhydrazino)carbonyl)benzenesulfonamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The results of our clinical trial showed that metipamide is an effective first-line antihypertensive agent, in that it combines satisfactory reduction of blood pressure with a low frequency of side-effects and a simple once-daily dosage regime."( Therapeutic monitoring of metipamide during antihypertensive therapy.
Grafnetterová, J; Klíma, J; Kubelka, Z, 1989
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]